Author

Rebecca L. Tombleson

Observed names: R L Tombleson, R Tombleson, Rebecca Tombleson

Institutions: University of South Carolina, Nova Southeastern University

Observed institutions: University of South Carolina, Nova Southeastern University, Moffitt Cancer Center

OpenAlex ID: A5048879869

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma

2014 · S R Parmar, R Bookout, et al. · Bone Marrow Transplantation · 25

Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists

2017 · Amy Bryk, Susannah Koontz, et al. · Journal of Oncology Pharmacy Practice · 15

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

2020 · Elizabeth DiMaggio, Jun-Min Zhou, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

2011 · Jamie Shapiro, Janelle Perkins, et al. · Blood · 8

High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma

2010 · Christopher J. Campen, Rebecca L. Tombleson, et al. · Journal of Neuro-Oncology · 8

Optimizing Premedications in the Prevention of Bendamustine Infusion-Related Reactions

2012 · Rebecca L. Tombleson, Viet Ho, et al. · Cancer Control · 4

Putting caution in TEAM: high-dose chemotherapy with autologous HSCT for primary central nervous system lymphoma

2012 · R L Tombleson, M R Green, et al. · Bone Marrow Transplantation · 3

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

2021 · Charles L. Bennett, Sumimasa Nagai, et al. · The Oncologist · 2

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

2016 · Justina Ofori Frimpong, Rebecca Tombleson, et al. · Blood · 2

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

2016 · Ryan James Caddell, Braydon Schaible, et al. · Blood · 1

Results of the American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Practice Survey – Understanding Today to Meet the Needs of Tomorrow

2015 · Ila Maewal Saunders, Amy W. Bryk, et al. · Transplantation and Cellular Therapy · 1

Reduced Intensity Fludarabine/Melphalan Has Similar Survival to Myeloablative Fludarabine/Busulfan (Targeted) in Patients with AML and MDS

2017 · Elizabeth DiMaggio, Rebecca Tombleson, et al. · Transplantation and Cellular Therapy

Characterization of Collaborative Practice Agreements (CPA) Held By Hematopoietic Cell Transplant (HCT) Pharmacists

2016 · Amy Wiglesworth Bryk, Susannah Koontz, et al. · Transplantation and Cellular Therapy

Evaluation of Melphalan 1-Day Versus 2-Day Dosing in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

2013 · Sapna Parmar, Ryan Bookout, et al. · Transplantation and Cellular Therapy

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

2010 · Rebecca Tombleson, Viet Q. Ho, et al. · Blood

Works count: 15

Citation count: 81

H-index: 5

I10-index: 3